Syros Pharmaceuticals, Inc.
(NASDAQ : SYRS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. -6.63%67.841.0%$1406.12m
BIIBBiogen, Inc. -1.75%304.661.5%$623.55m
REGNRegeneron Pharmaceuticals, Inc. -0.73%428.482.6%$521.18m
AMGNAmgen, Inc. -3.64%196.101.3%$507.28m
ILMNIllumina, Inc. -0.84%257.753.5%$392.52m
VRTXVertex Pharmaceuticals, Inc. -2.54%217.631.9%$339.58m
MRNAModerna, Inc. -12.66%22.850.0%$330.14m
ALXNAlexion Pharmaceuticals, Inc. -0.75%91.402.0%$219.05m
CODXCo-Diagnostics, Inc. -14.58%13.630.0%$211.27m
AAgilent Technologies, Inc. -2.93%75.161.6%$164.80m
EXASEXACT Sciences Corp. -0.93%80.0724.0%$162.09m
BMRNBioMarin Pharmaceutical, Inc. -1.10%88.834.3%$113.47m
INCYIncyte Corp. -2.53%73.922.5%$107.59m
SGENSeattle Genetics, Inc. 1.12%109.526.1%$107.08m
NVAXNovavax, Inc. 33.98%15.81184.0%$88.07m

Company Profile

Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyse unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. The firm focuses on developing treatments for cancer and immune mediated diseases and is building a pipeline of gene control medicines. The company was founded by Richard A. Young, Nathanael S. Gray and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.